Predict your next investment


See what CB Insights has to offer

About Choroideremia Research Foundation

Choroidermia Research Foundation provides funding to research on choroidermia.

Choroideremia Research Foundation Headquarter Location

23 East Brundreth Street

Springfield, Massachusetts, 01109,

United States


Latest Choroideremia Research Foundation News

Choroideremia Research Foundation Supports New Research to Expand Knowledge of This Rare Inherited Retinal Disease

Feb 1, 2021

Dr. Mariya Moosajee receives the Salois Family Research Award News provided by Share this article SPRINGFIELD, Mass., Feb. 1, 2021 /PRNewswire/ -- The Choroideremia Research Foundation (CRF) is pleased to announce funding for its first research study in 2021 to Mariya Moosajee, MBBS, BsC (Hons), PhD, FRCOphth. She is a consultant ophthalmic surgeon and clinical academic ophthalmologist with Moorefield Eye Hospital, University College, London. In recognition of Dr. Moosajee's long history of collaboration with the CRF, she has received the Salois Family Research Award. Dr. Mariya Moosajee In Dr. Moosajee's proposal, Neuroprotection for Choroideremia, she will continue her investigation of therapies for individuals with choroideremia. Using a well-established model of choroideremia (CHM) in zebrafish, she will examine how specific molecules may protect the nerves that are damaged in patients with CHM. As a translational research project, the hope is that positive study results will lead to clinical trials in humans. "We are very happy to again support the research of Dr. Moosajee who has been investigating potential treatment options for patients with choroideremia for many years," said Neal Bench, CRF board president. "We are grateful to jointly support this important research with the Choroideremia Research Foundation Canada." For more information about all research studies the CRF supports, please visit Media Contact: About Choroideremia Choroideremia (CHM) is a rare inherited form of blindness affecting approximately 1 in 50,000 people. Due to its x-linked inheritance pattern males are most severely affected with females usually experiencing much milder visual impairment. Symptoms begin in early childhood with night blindness and restriction of visual field being the earliest noticeable effects, eventually progressing to complete blindness. An estimated 6,000 people in the United States and 10,000 in the European Union are impacted by Choroideremia. There are currently no approved treatments for Choroideremia. About the Choroideremia Research Foundation Inc. The Choroideremia Research Foundation was founded in 2000 as an international fundraising and patient advocacy organization to stimulate research on CHM. Since its inception, the CRF has provided over $2.5 million in research awards and is the largest financial supporter of CHM research worldwide. Research funded by the CRF has led to the development of a CHM animal model, the pre-clinical production of gene therapy vectors currently in clinical trials, and the CRF Biobank which stores tissue and stem cell samples donated by CHM patients. For more information, visit SOURCE Choroideremia Research Foundation

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Choroideremia Research Foundation Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Choroideremia Research Foundation Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.